Spruce Biosciences, Inc.
SPRB
$0.0649
-$0.001-1.52%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 697.00K | 602.00K | 1.61M | 2.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 697.00K | 602.00K | 1.61M | 2.00M |
| Cost of Revenue | 10.84M | 21.46M | 6.55M | 8.09M | 10.32M |
| Gross Profit | -10.84M | -20.76M | -5.95M | -6.48M | -8.32M |
| SG&A Expenses | 3.66M | 3.31M | 3.46M | 3.56M | 4.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.49M | 24.77M | 10.01M | 11.65M | 14.64M |
| Operating Income | -14.49M | -24.07M | -9.41M | -10.04M | -12.63M |
| Income Before Tax | -14.04M | -23.56M | -8.67M | -9.18M | -11.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.04M | -23.56M | -8.67M | -9.18M | -11.63M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.04M | -23.56M | -8.67M | -9.18M | -11.63M |
| EBIT | -14.49M | -24.07M | -9.41M | -10.04M | -12.63M |
| EBITDA | -14.49M | -24.07M | -9.40M | -10.02M | -12.62M |
| EPS Basic | -0.32 | -0.57 | -0.21 | -0.22 | -0.28 |
| Normalized Basic EPS | -0.20 | -0.35 | -0.13 | -0.14 | -0.18 |
| EPS Diluted | -0.32 | -0.57 | -0.21 | -0.22 | -0.28 |
| Normalized Diluted EPS | -0.20 | -0.35 | -0.13 | -0.14 | -0.18 |
| Average Basic Shares Outstanding | 43.94M | 41.50M | 41.30M | 41.16M | 41.10M |
| Average Diluted Shares Outstanding | 43.94M | 41.50M | 41.30M | 41.16M | 41.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |